Beeline flies into phase 3 as oral lupus drug soars past placebo
A phase 2 trial of Beeline Medicines' afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
Useful takeaways from this story.
A phase 2 trial of Beeline Medicines' afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
A phase 2 trial of Beeline Medicines' afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.